202 related articles for article (PubMed ID: 23332809)
41. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?
Taranu A; Colle R; Gressier F; El Asmar K; Becquemont L; Corruble E; Verstuyft C
Pharmacogenomics; 2017 May; 18(7):639-650. PubMed ID: 28480819
[TBL] [Abstract][Full Text] [Related]
42. Distribution of venlafaxine, O-desmethylvenlafaxine, and O-desmethylvenlafaxine to venlafaxine ratio in postmortem human brain tissue.
Murrell MD; Cruz DA; Javors MA; Thompson PM
J Forensic Sci; 2014 May; 59(3):683-9. PubMed ID: 24502274
[TBL] [Abstract][Full Text] [Related]
43. Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients.
Haslemo T; Eliasson E; Jukić MM; Ingelman-Sundberg M; Molden E
Br J Clin Pharmacol; 2019 Jan; 85(1):194-201. PubMed ID: 30312494
[TBL] [Abstract][Full Text] [Related]
44. Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers.
Fukuda T; Yamamoto I; Nishida Y; Zhou Q; Ohno M; Takada K; Azuma J
Br J Clin Pharmacol; 1999 Apr; 47(4):450-3. PubMed ID: 10233212
[TBL] [Abstract][Full Text] [Related]
45. The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions.
Unterecker S; Hiemke C; Greiner C; Haen E; Jabs B; Deckert J; Pfuhlmann B
Pharmacopsychiatry; 2012 Sep; 45(6):229-35. PubMed ID: 22426847
[TBL] [Abstract][Full Text] [Related]
46. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
47. Oxycodone findings and CYP2D6 function in postmortem cases.
Jakobsson G; Larsson R; Pellè L; Kronstrand R; Gréen H
Forensic Sci Int Genet; 2021 Jul; 53():102510. PubMed ID: 33799050
[TBL] [Abstract][Full Text] [Related]
48. Comparison of analytical methods in the determination of two venlafaxine fatalities.
Long C; Crifasi J; Maginn D; Graham M; Teas S
J Anal Toxicol; 1997; 21(2):166-9. PubMed ID: 9083836
[TBL] [Abstract][Full Text] [Related]
49. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans.
Lessard E; Yessine MA; Hamelin BA; Gauvin C; Labbé L; O'Hara G; LeBlanc J; Turgeon J
J Clin Psychopharmacol; 2001 Apr; 21(2):175-84. PubMed ID: 11270914
[TBL] [Abstract][Full Text] [Related]
50. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.
Lindh JD; Annas A; Meurling L; Dahl ML; AL-Shurbaji A
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):401-6. PubMed ID: 12898080
[TBL] [Abstract][Full Text] [Related]
51. Understanding outliers on the usual dose-response curve: venlafaxine as a way to phenotype patients in terms of their CYP 2D6 status and why it matters.
Preskorn SH
J Psychiatr Pract; 2010 Jan; 16(1):46-9. PubMed ID: 20098230
[TBL] [Abstract][Full Text] [Related]
52. The comparison of brand-name and generic formulations of venlafaxine: a therapeutic drug monitoring analysis.
Unterecker S; Proft F; Riederer P; Lauer M; Deckert J; Pfuhlmann B
Ther Drug Monit; 2014 Apr; 36(2):269-72. PubMed ID: 24365982
[TBL] [Abstract][Full Text] [Related]
53. Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine.
Kowalewski C; Haen E; Hiemke C; Ridders F; Endres K; Gründer G; Paulzen M; Schoretsanitis G
Int Clin Psychopharmacol; 2019 Sep; 34(5):241-246. PubMed ID: 31094902
[TBL] [Abstract][Full Text] [Related]
54. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
Lessard E; Yessine MA; Hamelin BA; O'Hara G; LeBlanc J; Turgeon J
Pharmacogenetics; 1999 Aug; 9(4):435-43. PubMed ID: 10780263
[TBL] [Abstract][Full Text] [Related]
55. A fatal doxepin poisoning associated with a defective CYP2D6 genotype.
Koski A; Ojanperä I; Sistonen J; Vuori E; Sajantila A
Am J Forensic Med Pathol; 2007 Sep; 28(3):259-61. PubMed ID: 17721180
[TBL] [Abstract][Full Text] [Related]
56. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression.
Ng C; Sarris J; Singh A; Bousman C; Byron K; Peh LH; Smith DJ; Tan CH; Schweitzer I
Hum Psychopharmacol; 2013 Sep; 28(5):516-22. PubMed ID: 24014145
[TBL] [Abstract][Full Text] [Related]
57. PharmGKB summary: venlafaxine pathway.
Sangkuhl K; Stingl JC; Turpeinen M; Altman RB; Klein TE
Pharmacogenet Genomics; 2014 Jan; 24(1):62-72. PubMed ID: 24128936
[No Abstract] [Full Text] [Related]
58. Rapid high-performance liquid chromatographic measurement of venlafaxine and O-desmethylvenlafaxine in human plasma. Application to management of acute intoxications.
Matoga M; Pehourcq F; Titier K; Dumora F; Jarry C
J Chromatogr B Biomed Sci Appl; 2001 Sep; 760(2):213-8. PubMed ID: 11530979
[TBL] [Abstract][Full Text] [Related]
59. Correlation of genotype, phenotype, and mRNA expression of CYP2D6 and CYP2C19 in peripheral blood leukocytes (PBLs).
Kuhlmann JB; Wensing G; Kuhlmann J
Int J Clin Pharmacol Ther; 2014 Feb; 52(2):143-50. PubMed ID: 24361088
[TBL] [Abstract][Full Text] [Related]
60. Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine.
Kuzin M; Schoretsanitis G; Haen E; Stegmann B; Hiemke C; Gründer G; Paulzen M
Clin Pharmacokinet; 2018 Jun; 57(6):729-737. PubMed ID: 28866861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
